Consolidative PD-L1 inhibitors after concurrent chemoradiotherapy (cCRT) have become standard care in locally advanced non-small cell lung cancer (LA-NSCLC).
However, the correlation between immune-related adverse event (irAE) characteristics and patient outcomes remains unclear.
